• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缓解颈部肌肉紧张可改善心理压力及中重度特应性皮炎症状:20例患者的病例系列研究

Release of Cervical Muscle Tension Improves Psychological Stress and Symptoms of Moderate-to-Severe Atopic Dermatitis: a Case Series with 20 Patients.

作者信息

Hosono Shusaku, Fujita Koji, Nimura Akimoto, Akita Keiichi

机构信息

Department of Clinical Anatomy, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Department of Dermatology, Hosono Clinic, Tokyo, Japan.

出版信息

Dermatol Ther (Heidelb). 2022 Oct;12(10):2383-2395. doi: 10.1007/s13555-022-00814-x. Epub 2022 Sep 21.

DOI:10.1007/s13555-022-00814-x
PMID:36129669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9515250/
Abstract

INTRODUCTION

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that is triggered by intense pruritus, impaired skin barrier function, and immune responses to allergenic substances. Break-through therapies for AD include molecular-targeted drugs and the effective management of severe symptoms of AD. However, patients with clinical improvements may continue scratching owing to the influence of psychological stress, which might lead to quick relapses of stressors and subsequent intensive scratching. New drugs may be ineffective because of such scratching behavior caused by stressors. Therefore, it may be useful to consider adjunctive treatment options that focus on external stressors as triggers of deterioration of AD. We hypothesized that improvement of psychological stress by relieving cervical muscle tension would reduce pruritus and atopic symptoms.

METHODS

Overall, 21 patients with moderate-to-severe AD were treated to relieve cervical muscular tension using Spineliner SA201, which assists in osteopathic manipulative treatment. We assessed the subjective and objective symptoms of AD, cervical muscle tension, which was evaluated using cervical range of motion (ROM), and psychological burden. Only moisturizers were applied topically during the study period, and no topical corticosteroid therapy was used.

RESULTS

Twenty patients who completed the treatment demonstrated improvement in the symptoms of AD: changes on the visual analog scale (VAS) for pruritus were -44.2%, Eczema Area and Severity Index (EASI) was -67.9%, thymus and activation-regulated chemokine (TARC) was -56.2%, Hospital Anxiety and Depression Scale (HADS) was -27.2%, sleep disturbance was -49.7%, and Dermatology Life Quality Index (DLQI) was -46.7%. Additionally, the cervical muscle tension improved significantly: changes in cervical ROM were 14.7%.

CONCLUSIONS

Release of cervical muscle tension may improve psychological stress and have an effect on moderate-to-severe AD.

摘要

引言

特应性皮炎(AD)是一种慢性复发性炎症性皮肤病,由剧烈瘙痒、皮肤屏障功能受损以及对变应原物质的免疫反应引发。AD的突破性治疗方法包括分子靶向药物以及对AD严重症状的有效管理。然而,临床症状有所改善的患者可能会由于心理压力的影响而继续搔抓,这可能导致应激源迅速复发并随后引发剧烈搔抓。由于应激源导致的这种搔抓行为,新药可能无效。因此,考虑将关注外部应激源作为AD病情恶化触发因素的辅助治疗方案可能会有所帮助。我们假设通过缓解颈部肌肉紧张来改善心理压力会减轻瘙痒和特应性症状。

方法

总体而言,21例中重度AD患者使用Spineliner SA201进行治疗以缓解颈部肌肉紧张,该设备有助于整骨手法治疗。我们评估了AD的主观和客观症状、使用颈部活动范围(ROM)评估的颈部肌肉紧张以及心理负担。在研究期间仅局部应用保湿剂,未使用局部糖皮质激素治疗。

结果

完成治疗的20例患者AD症状有所改善:瘙痒视觉模拟量表(VAS)变化为-44.2%,湿疹面积和严重程度指数(EASI)为-67.9%,胸腺和活化调节趋化因子(TARC)为-56.2%,医院焦虑抑郁量表(HADS)为-27.2%,睡眠障碍为-49.7%,皮肤病生活质量指数(DLQI)为-46.7%。此外,颈部肌肉紧张明显改善:颈部ROM变化为14.7%。

结论

缓解颈部肌肉紧张可能会改善心理压力并对中重度AD产生影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb3/9515250/7475d75b748d/13555_2022_814_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb3/9515250/8b7093823b3e/13555_2022_814_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb3/9515250/8c7919812aa5/13555_2022_814_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb3/9515250/7475d75b748d/13555_2022_814_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb3/9515250/8b7093823b3e/13555_2022_814_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb3/9515250/8c7919812aa5/13555_2022_814_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb3/9515250/7475d75b748d/13555_2022_814_Fig3_HTML.jpg

相似文献

1
Release of Cervical Muscle Tension Improves Psychological Stress and Symptoms of Moderate-to-Severe Atopic Dermatitis: a Case Series with 20 Patients.缓解颈部肌肉紧张可改善心理压力及中重度特应性皮炎症状:20例患者的病例系列研究
Dermatol Ther (Heidelb). 2022 Oct;12(10):2383-2395. doi: 10.1007/s13555-022-00814-x. Epub 2022 Sep 21.
2
Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series.缓解颈部肌肉紧张改善中重度特应性皮炎的严重瘙痒:病例系列
JAAD Case Rep. 2020 Apr 24;6(6):510-513. doi: 10.1016/j.jdcr.2020.03.018. eCollection 2020 Jun.
3
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).乌帕替尼可迅速改善特应性皮炎患者报告的结局:3期临床试验(Measure Up 1和2)的16周结果
Dermatol Ther (Heidelb). 2024 May;14(5):1127-1144. doi: 10.1007/s13555-024-01157-5. Epub 2024 May 2.
4
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.来布立izumab治疗中度至重度特应性皮炎青少年患者的安全性和有效性:一项为期52周的开放标签3期研究。
Dermatol Ther (Heidelb). 2023 Jul;13(7):1517-1534. doi: 10.1007/s13555-023-00942-y. Epub 2023 Jun 15.
5
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.度普利尤单抗治疗中度至重度特应性皮炎且既往使用过全身性非甾体免疫抑制剂的成人患者:四项3期试验分析
Dermatol Ther (Heidelb). 2021 Aug;11(4):1357-1372. doi: 10.1007/s13555-021-00558-0. Epub 2021 Jun 18.
6
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中,度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
7
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.度普利尤单抗可改善中重度特应性皮炎患者的报告症状、焦虑和抑郁症状以及健康相关生活质量:来自随机试验 SOLO 1 和 SOLO 2 的汇总数据分析。
J Dermatolog Treat. 2020 Sep;31(6):606-614. doi: 10.1080/09546634.2019.1612836. Epub 2019 Jun 9.
8
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.度普利尤单抗治疗特应性皮炎患者的长期疗效:RELIEVE-AD研究3年随访结果
Dermatol Ther (Heidelb). 2023 Sep;13(9):2107-2120. doi: 10.1007/s13555-023-00965-5. Epub 2023 Aug 8.
9
Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.特应性皮炎成人患者疾病控制不佳和疾病严重程度与患者报告疾病负担的相关性。
JAMA Dermatol. 2018 Aug 1;154(8):903-912. doi: 10.1001/jamadermatol.2018.1572.
10
Alterations in Brain Neural Network and Stress System in Atopic Dermatitis: Novel Therapeutic Interventions.特应性皮炎患者脑神经网络和应激系统的改变:新型治疗干预措施
J Pharmacol Exp Ther. 2023 May;385(2):78-87. doi: 10.1124/jpet.122.001482. Epub 2023 Feb 24.

引用本文的文献

1
Integrative Treatment Approaches with Mind-Body Therapies in the Management of Atopic Dermatitis.在特应性皮炎管理中采用身心疗法的综合治疗方法。
J Clin Med. 2024 Sep 11;13(18):5368. doi: 10.3390/jcm13185368.
2
Interventions for anxiety and depression in patients with atopic dermatitis: a systematic review and meta-analysis.特应性皮炎患者焦虑和抑郁的干预措施:系统评价和荟萃分析。
Sci Rep. 2024 Apr 17;14(1):8844. doi: 10.1038/s41598-024-59162-9.
3
Atopic Dermatitis: Beyond the Skin and Into the Gut.特应性皮炎:超越皮肤,深入肠道。

本文引用的文献

1
Stress and Skin: An Overview of Mind Body Therapies as a Treatment Strategy in Dermatology.压力与皮肤:身心疗法作为皮肤科治疗策略的概述
Dermatol Pract Concept. 2021 Sep 1;11(4):e2021091. doi: 10.5826/dpc.1104a91. eCollection 2021 Sep.
2
Current Clinical Options for the Management of Itch in Atopic Dermatitis.特应性皮炎瘙痒管理的当前临床选择
Clin Cosmet Investig Dermatol. 2021 Aug 3;14:959-969. doi: 10.2147/CCID.S289716. eCollection 2021.
3
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
J Clin Med. 2023 Aug 25;12(17):5534. doi: 10.3390/jcm12175534.
乌帕替尼对比度普利尤单抗治疗成人中重度特应性皮炎的疗效和安全性:一项随机临床试验。
JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023.
4
Quality of Life and Psychological Impact in Patients with Atopic Dermatitis.特应性皮炎患者的生活质量和心理影响
J Clin Med. 2021 Mar 21;10(6):1298. doi: 10.3390/jcm10061298.
5
Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.度普利尤单抗治疗可改善特应性皮炎患者的临床和血液学症状,包括血液嗜酸性粒细胞增多。
Int J Dermatol. 2021 Feb;60(2):190-195. doi: 10.1111/ijd.15183. Epub 2020 Sep 29.
6
Can moderate-intensity aerobic exercise ameliorate atopic dermatitis?中等强度的有氧运动可以改善特应性皮炎吗?
Exp Dermatol. 2020 Aug;29(8):699-702. doi: 10.1111/exd.14138. Epub 2020 Jul 20.
7
Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series.缓解颈部肌肉紧张改善中重度特应性皮炎的严重瘙痒:病例系列
JAAD Case Rep. 2020 Apr 24;6(6):510-513. doi: 10.1016/j.jdcr.2020.03.018. eCollection 2020 Jun.
8
Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis.特应性皮炎中嗜酸性粒细胞、嗜碱性粒细胞、血清总 IgE 水平、过敏原特异性 IgE 和临床特征的临床相关性。
J Clin Lab Anal. 2020 Jun;34(6):e23214. doi: 10.1002/jcla.23214. Epub 2020 Feb 18.
9
Acupuncture Treatment for Symptom Management in Atopic Dermatitis: A Study Protocol for a Randomized, Participant- and Assessor-Blind, Sham-Controlled Trial.针刺疗法用于特应性皮炎症状管理:一项随机、参与者和评估者双盲、假针刺对照试验的研究方案
Evid Based Complement Alternat Med. 2019 May 2;2019:1907578. doi: 10.1155/2019/1907578. eCollection 2019.
10
How acute stress impacts the itch-scratch cycle in atopic dermatitis: a clinical lesson.急性应激如何影响特应性皮炎的瘙痒-搔抓循环:临床经验教训。
Br J Dermatol. 2019 Apr;180(4):689-690. doi: 10.1111/bjd.17114.